These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 15586222

  • 1. Combination of vitamin K2 plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer cell lines.
    Yokoyama T, Miyazawa K, Yoshida T, Ohyashiki K.
    Int J Oncol; 2005 Jan; 26(1):33-40. PubMed ID: 15586222
    [Abstract] [Full Text] [Related]

  • 2. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer.
    Wolff NC, Randle DE, Egorin MJ, Minna JD, Ilaria RL.
    Clin Cancer Res; 2004 May 15; 10(10):3528-34. PubMed ID: 15161712
    [Abstract] [Full Text] [Related]

  • 3. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
    Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, Stiles CD, Griffin JD, Johnson BE, Salgia R.
    Oncogene; 2000 Jul 20; 19(31):3521-8. PubMed ID: 10918610
    [Abstract] [Full Text] [Related]

  • 4. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling.
    Weigel MT, Meinhold-Heerlein I, Bauerschlag DO, Schem C, Bauer M, Jonat W, Maass N, Mundhenke C.
    Cancer Lett; 2009 Jan 08; 273(1):70-9. PubMed ID: 18809244
    [Abstract] [Full Text] [Related]

  • 5. Combined treatment of leukemia cells with vitamin K2 and 1alpha,25-dihydroxy vitamin D3 enhances monocytic differentiation along with becoming resistant to apoptosis by induction of cytoplasmic p21CIP1.
    Iguchi T, Miyazawa K, Asada M, Gotoh A, Mizutani S, Ohyashiki K.
    Int J Oncol; 2005 Oct 08; 27(4):893-900. PubMed ID: 16142303
    [Abstract] [Full Text] [Related]

  • 6. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK, Rahmani M, Gao N, Kramer L, Corbin AS, Druker BJ, Dent P, Grant S.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [Abstract] [Full Text] [Related]

  • 7. Apoptosis induction of vitamin K2 in lung carcinoma cell lines: the possibility of vitamin K2 therapy for lung cancer.
    Yoshida T, Miyazawa K, Kasuga I, Yokoyama T, Minemura K, Ustumi K, Aoshima M, Ohyashiki K.
    Int J Oncol; 2003 Sep 01; 23(3):627-32. PubMed ID: 12888897
    [Abstract] [Full Text] [Related]

  • 8. [Effect of tyrosine kinase inhibitor Imatinib mesylate on proliferation, differentiation and apoptosis of Kasumi-1 leukemia cell line].
    Wang LH, Rao Q, Wang M, Wang JX.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Aug 01; 26(8):449-52. PubMed ID: 16383232
    [Abstract] [Full Text] [Related]

  • 9. Differential tyrosine phosphorylation of leukemic cells during apoptosis as a result of treatment with imatinib mesylate.
    Park J, Kim S, Oh C, Yoon SS, Lee D, Kim Y.
    Biochem Biophys Res Commun; 2005 Oct 28; 336(3):942-51. PubMed ID: 16157305
    [Abstract] [Full Text] [Related]

  • 10. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
    Krug LM, Crapanzano JP, Azzoli CG, Miller VA, Rizvi N, Gomez J, Kris MG, Pizzo B, Tyson L, Dunne M, Heelan RT.
    Cancer; 2005 May 15; 103(10):2128-31. PubMed ID: 15812822
    [Abstract] [Full Text] [Related]

  • 11. Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.
    La Rosée P, Jia T, Demehri S, Härtel N, de Vries P, Bonham L, Hollenback D, Singer JW, Melo JV, Druker BJ, Deininger MW.
    Clin Cancer Res; 2006 Nov 01; 12(21):6540-6. PubMed ID: 17085669
    [Abstract] [Full Text] [Related]

  • 12. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate.
    Shaw TJ, Vanderhyden BC.
    Gynecol Oncol; 2007 Apr 01; 105(1):122-31. PubMed ID: 17169414
    [Abstract] [Full Text] [Related]

  • 13. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
    Irsan I, Akisue T, Hara H, Fujimoto T, Imabori M, Doita M, Kuroda R, Fujioka H, Kawamoto T, Yamamoto T, Kurosaka M.
    Anticancer Res; 2007 Apr 01; 27(1A):423-9. PubMed ID: 17352263
    [Abstract] [Full Text] [Related]

  • 14. Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro.
    Zhang P, Gao WY, Turner S, Ducatman BS.
    Mol Cancer; 2003 Jan 03; 2():1. PubMed ID: 12537587
    [Abstract] [Full Text] [Related]

  • 15. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M, Nguyen TK, Dent P, Grant S.
    Mol Pharmacol; 2007 Sep 03; 72(3):788-95. PubMed ID: 17595328
    [Abstract] [Full Text] [Related]

  • 16. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
    Wang-Rodriguez J, Lopez JP, Altuna X, Chu TS, Weisman RA, Ongkeko WM.
    Laryngoscope; 2006 Aug 03; 116(8):1409-16. PubMed ID: 16885745
    [Abstract] [Full Text] [Related]

  • 17. N-acetyl cysteine enhances imatinib-induced apoptosis of Bcr-Abl+ cells by endothelial nitric oxide synthase-mediated production of nitric oxide.
    Rakshit S, Bagchi J, Mandal L, Paul K, Ganguly D, Bhattacharjee S, Ghosh M, Biswas N, Chaudhuri U, Bandyopadhyay S.
    Apoptosis; 2009 Mar 03; 14(3):298-308. PubMed ID: 19153832
    [Abstract] [Full Text] [Related]

  • 18. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
    Basciani S, Brama M, Mariani S, De Luca G, Arizzi M, Vesci L, Pisano C, Dolci S, Spera G, Gnessi L.
    Cancer Res; 2005 Mar 01; 65(5):1897-903. PubMed ID: 15753388
    [Abstract] [Full Text] [Related]

  • 19. Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity.
    Hawkins LM, Jayanthan AA, Narendran A.
    Pediatr Res; 2005 Mar 01; 57(3):430-7. PubMed ID: 15659698
    [Abstract] [Full Text] [Related]

  • 20. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
    Johnson FM, Saigal B, Donato NJ.
    J Cell Physiol; 2005 Nov 01; 205(2):218-27. PubMed ID: 15887238
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.